person · Reporting owner

Silverman Joshua

Disclosed activity across 10 companies

Tapewire entity: 23501
SEC CIK: 0001524858

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Fabric.AI, Inc.FABC · Entity 7732	Director · Chief Executive Officer	June 18, 2026	August 14, 2026
NATIONAL HOLDINGS CORPNHLD · Entity 142239	Director	September 12, 2016	September 13, 2016
Neurotrope, Inc.NTRP · Entity 144906	Director	December 01, 2020	December 03, 2020
Petros Pharmaceuticals, Inc.PTPI · Entity 8730	Director	June 05, 2026	June 05, 2026
PharmaCyte Biotech, Inc.PMCB · Entity 8256	Director · CEO and President	January 05, 2026	January 07, 2026
Protagenic Therapeutics, Inc.\newPTIX · Entity 8496	Director	February 21, 2020	February 27, 2020
Q/C TECHNOLOGIES, INC.QCLS · Entity 7735	Director · Executive Chairman	July 10, 2026	October 03, 2026
TAO Synergies Inc.TAOX · Entity 7482	Director · Executive Chairman	May 18, 2026	May 19, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Fabric.AI, Inc.

Report date June 18, 2026 · Filed August 14, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	280,757	Ending reported balance After 2026-06-30 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-06-18 · Grant · Acquired 358,565 · Balance 370,397 F1: Represents a grant of restricted shares (the "Stock Award") of common stock, par value $0.0001 per share ("Common Stock"), of the Issuer granted to the Reporting Person under the Fabric.AI, Inc. Long-Term Incentive Plan (as amended, the "Plan"). The Stock Award vests as follows: (i) 25% vested on June 18, 2026, (ii) 25% vested on June 30, 2026, (iii) 25% will vest on September 30, 2026, and (iv) 25% will vest on December 31, 2026. Row 2 · 2026-06-18 · Tax withholding · Disposed 44,820 · Balance 325,577 Row 3 · 2026-06-30 · Tax withholding · Disposed 44,820 · Balance 280,757

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of restricted shares (the "Stock Award") of common stock, par value $0.0001 per share ("Common Stock"), of the Issuer granted to the Reporting Person under the Fabric.AI, Inc. Long-Term Incentive Plan (as amended, the "Plan"). The Stock Award vests as follows: (i) 25% vested on June 18, 2026, (ii) 25% vested on June 30, 2026, (iii) 25% will vest on September 30, 2026, and (iv) 25% will vest on December 31, 2026.

NATIONAL HOLDINGS CORP

Report date September 12, 2016 · Filed September 13, 2016

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.02 per shareSEC Table I · non-derivative	IndirectSee Footnote	414,323	Reported balance After 2016-09-12 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2016-09-12 · Other · Acquired 414,323 · Balance 414,323 F1: Securities validly tendered by Iroquois Master Fund (the "Fund") in the tender offer by FBIO Acquisition, Inc., a wholly-owned subsidiary of Fortress Biotech, Inc. Mr. Silverman disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: Securities validly tendered by Iroquois Master Fund (the "Fund") in the tender offer by FBIO Acquisition, Inc., a wholly-owned subsidiary of Fortress Biotech, Inc. Mr. Silverman disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Neurotrope, Inc.

Report date December 01, 2020 · Filed December 03, 2020

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-12-01 transaction · row 1 1 source row Row 1 · 2020-12-01 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.20	Direct	Reported balance After 2020-12-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-12-01 · Disposition to issuer · Disposed 9,375 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.56	Direct	Reported balance After 2020-12-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-12-01 · Disposition to issuer · Disposed 124,275 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.10	Direct	Reported balance After 2020-12-01 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.62	Direct	Reported balance After 2020-12-01 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-12-01 · Disposition to issuer · Disposed 167,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.91	Direct	Reported balance After 2020-12-01 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93	Direct	Reported balance After 2020-12-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-12-01 · Disposition to issuer · Disposed 150,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.06	Direct	Reported balance After 2020-12-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82	Direct	Reported balance After 2020-12-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-12-01 · Disposition to issuer · Disposed 10,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.97	Direct	Reported balance After 2020-12-01 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2020-12-01 · Disposition to issuer · Disposed 100,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held.

F2: Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held.

Petros Pharmaceuticals, Inc.

Report date June 05, 2026 · Filed June 05, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	8,790,450	Reported balance After 2026-06-05 transaction · row 1 1 source row Row 1 · 2026-06-05 · Grant · Acquired 4,375,000 · Balance 8,790,450 F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date.

PharmaCyte Biotech, Inc.

Report date January 05, 2026 · Filed January 07, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	416,250	Ending reported balance After 2026-01-07 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-01-05 · Purchase · Acquired 30,000 · Balance 346,250 Row 2 · 2026-01-06 · Purchase · Acquired 30,000 · Balance 376,250 Row 3 · 2026-01-07 · Purchase · Acquired 40,000 · Balance 416,250
Common StockSEC Table I · non-derivative	IndirectJNS Holdings Group LLC	50,000	Reported balance Holding disclosure · report date 2026-01-05 · row 4 Holding and transaction disclosures are not merged. 1 source row Row 4 · Balance 50,000

Protagenic Therapeutics, Inc.\new

Report date February 21, 2020 · Filed February 27, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
PTIX Common stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2030-02-21	Direct	120,000	Reported balance After 2020-02-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-02-21 · Grant · Acquired 120,000 · Balance 120,000

Q/C TECHNOLOGIES, INC.

Report date July 10, 2026 · Filed October 03, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	210,845	Ending reported balance After 2026-10-01 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-07-10 · Grant · Acquired 16,620 · Balance 133,455 F1: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person (the "Compensation Agreement") providing for quarterly grants equal to $60,000. The Restricted Stock vested pursuant to the terms of the Compensation Agreement. Row 2 · 2026-10-01 · Grant · Acquired 77,390 · Balance 210,845 F2: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to the Compensation Agreement. The Restricted Stock vested pursuant to the terms of the Compensation Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person (the "Compensation Agreement") providing for quarterly grants equal to $60,000. The Restricted Stock vested pursuant to the terms of the Compensation Agreement.

F2: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to the Compensation Agreement. The Restricted Stock vested pursuant to the terms of the Compensation Agreement.

TAO Synergies Inc.

Report date May 18, 2026 · Filed May 19, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.80 · Expires 2036-05-18	Direct	200,000	Reported balance After 2026-05-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-18 · Grant · Acquired 200,000 · Balance 200,000 F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

FEMASYS INC

Report date March 17, 2026 · Filed March 18, 2026

Section 16 reporting ended · disclosed 2026-03-18. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Marker Therapeutics, Inc.

Report date October 16, 2018 · Filed October 17, 2018

Section 16 reporting ended · disclosed 2018-10-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	17,221	Reported balance After 2018-10-16 transaction · row 1 1 source row Row 1 · 2018-10-16 · Grant · Acquired 4,106 · Balance 17,221 F1: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 2018 annual meeting.
Common StockSEC Table I · non-derivative	IndirectBy JNS Holdings Group LLC	153,333	Reported balance Holding disclosure · report date 2018-10-16 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 153,333

Filing footnotes · ownership attribution and instrument terms

F1: Represents the pro-rated portion of the annual board retainer for each non-employee director payable in immediately vested, common stock under the Company's 2014 Omnibus Stock Ownership Plan, as amended and based on the closing price of $7.74 per share, on the day immediately preceding the date of the Company's 2018 annual meeting.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
October 01, 2026 Filed Oct 3, 2026 01:02 UTC	Q/C TECHNOLOGIES, INC. QCLS · Entity 7735	GrantCommon Stock	77,390	$0.00	$0.00	Disclosure SEC source: 0001493152-26-045586 · ownership.xml · nonDerivative · entry 2 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,845 F2 · price: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to the Compensation Agreement. The Restricted Stock vested pursuant to the terms of the Compensation Agreement. Read SEC document
July 10, 2026 Filed Oct 3, 2026 01:02 UTC	Q/C TECHNOLOGIES, INC. QCLS · Entity 7735	GrantCommon Stock	16,620	$0.00	$0.00	Disclosure SEC source: 0001493152-26-045586 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,455 F1 · price: Represents a grant of Restricted Stock. The Restricted Stock was granted to the Reporting Person pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person (the "Compensation Agreement") providing for quarterly grants equal to $60,000. The Restricted Stock vested pursuant to the terms of the Compensation Agreement. Read SEC document
June 30, 2026 Filed Aug 14, 2026 20:35 UTC	Fabric.AI, Inc. FABC · Entity 7732	Tax withholdingCommon Stock	44,820	$3.69	$165,385.80	Disclosure SEC source: 0001493152-26-038455 · ownership.xml · nonDerivative · entry 3 Silverman Joshua · CIK 0001524858 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 280,757 Read SEC document
June 18, 2026 Filed Aug 14, 2026 20:35 UTC	Fabric.AI, Inc. FABC · Entity 7732	Tax withholdingCommon Stock	44,820	$3.70	$165,834.00	Disclosure SEC source: 0001493152-26-038455 · ownership.xml · nonDerivative · entry 2 Silverman Joshua · CIK 0001524858 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 325,577 Read SEC document
June 18, 2026 Filed Aug 14, 2026 20:35 UTC	Fabric.AI, Inc. FABC · Entity 7732	GrantCommon Stock	358,565	$0.00	$0.00	Disclosure SEC source: 0001493152-26-038455 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,397 F1 · kind: Represents a grant of restricted shares (the "Stock Award") of common stock, par value $0.0001 per share ("Common Stock"), of the Issuer granted to the Reporting Person under the Fabric.AI, Inc. Long-Term Incentive Plan (as amended, the "Plan"). The Stock Award vests as follows: (i) 25% vested on June 18, 2026, (ii) 25% vested on June 30, 2026, (iii) 25% will vest on September 30, 2026, and (iv) 25% will vest on December 31, 2026. F1 · price: Represents a grant of restricted shares (the "Stock Award") of common stock, par value $0.0001 per share ("Common Stock"), of the Issuer granted to the Reporting Person under the Fabric.AI, Inc. Long-Term Incentive Plan (as amended, the "Plan"). The Stock Award vests as follows: (i) 25% vested on June 18, 2026, (ii) 25% vested on June 30, 2026, (iii) 25% will vest on September 30, 2026, and (iv) 25% will vest on December 31, 2026. Read SEC document
June 05, 2026 Filed Jun 5, 2026 21:12 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantCommon Stock	4,375,000	$0.00	$0.00	Disclosure SEC source: 0001104659-26-071038 · tm2617013-4_4seq1.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,790,450 F1 · shares: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. F1 · price: Represents restricted shares ("Shares") of common stock, par value $0.0001 per share, of the Issuer. 50% of the Shares vested on the date of grant and the remaining 50% will vest on the six-month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Read SEC document
May 18, 2026 Filed May 19, 2026 22:45 UTC	TAO Synergies Inc. TAOX · Entity 7482	GrantStock Option (Right to Buy) · Derivative	200,000	$0.00 Strike: $4.80	$0.00	Disclosure SEC source: 0001104659-26-063996 · tm2615135-5_4seq1.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock, par value $0.0001 per share · 200,000 shares Expires 2036-05-18 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following May 18, 2026. Read SEC document
April 13, 2026 Filed Oct 3, 2026 01:00 UTC Amendment	Q/C TECHNOLOGIES, INC. QCLS · Entity 7735	GrantEmployee Stock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $5.00	$0.00	Disclosure SEC source: 0001493152-26-045576 · ownership.xml · derivative · entry 2 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2036-04-13 F2 · derivative.expiration_date: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer. Read SEC document
April 13, 2026 Filed Oct 3, 2026 01:00 UTC Amendment	Q/C TECHNOLOGIES, INC. QCLS · Entity 7735	GrantCommon Stock	16,806	$0.00	$0.00	Disclosure SEC source: 0001493152-26-045576 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,835 F1 · security: Represents a grant of RSUs issued pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person. The RSUs vested immediately upon grant on April 13, 2026. F1 · price: Represents a grant of RSUs issued pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person. The RSUs vested immediately upon grant on April 13, 2026. F3 · balance_after: Amount Beneficially Owned Following Transaction has been corrected from 262,191 to 116,835. Read SEC document
April 13, 2026 Filed Apr 15, 2026 22:29 UTC	Q/C TECHNOLOGIES, INC. QCLS · Entity 7735	GrantEmployee Stock Option (Right to Buy) · Derivative	100,000	$0.00 Strike: $5.00	$0.00	Disclosure SEC source: 0001493152-26-016912 · ownership.xml · derivative · entry 2 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 100,000 shares Expires 2036-04-13 F2 · derivative.expiration_date: The stock options are subject to expiration if the Reporting Person ceases to be employed by or provide services to the Issuer. Read SEC document
April 13, 2026 Filed Apr 15, 2026 22:29 UTC	Q/C TECHNOLOGIES, INC. QCLS · Entity 7735	GrantCommon stock	162,162	$0.00	$0.00	Disclosure SEC source: 0001493152-26-016912 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,191 F1 · price: Represents a grant of Restricted Stock Units ("RSUs") issued pursuant to an executive compensation agreement, dated April 13, 2026, by and between the Issuer and the Reporting Person. The RSUs vested immediately upon grant on April 13, 2026. Read SEC document
January 07, 2026 Filed Jan 7, 2026 22:43 UTC	PharmaCyte Biotech, Inc. PMCB · Entity 8256	PurchaseCommon Stock	40,000	$0.83	$33,316.00	Disclosure SEC source: 0001683168-26-000148 · ownership.xml · nonDerivative · entry 3 Silverman Joshua · CIK 0001524858 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,250 Read SEC document
January 06, 2026 Filed Jan 7, 2026 22:43 UTC	PharmaCyte Biotech, Inc. PMCB · Entity 8256	PurchaseCommon Stock	30,000	$0.79	$23,667.00	Disclosure SEC source: 0001683168-26-000148 · ownership.xml · nonDerivative · entry 2 Silverman Joshua · CIK 0001524858 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 376,250 Read SEC document
January 05, 2026 Filed Jan 7, 2026 22:43 UTC	PharmaCyte Biotech, Inc. PMCB · Entity 8256	PurchaseCommon Stock	30,000	$0.78	$23,493.00	Disclosure SEC source: 0001683168-26-000148 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,250 Read SEC document
January 02, 2026 Filed Jan 2, 2026 22:00 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantCommon Stock	4,375,000	$0.00	$0.00	Disclosure SEC source: 0001104659-26-000238 · tm261718-4_4seq1.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,415,450 F1 · shares: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer. F1 · price: Represents Restricted Stock Units ("RSUs"). 50% of the RSUs vested on the date of grant and the remaining 50% will vest on the six month anniversary of the date of grant, provided that the Reporting Person is providing services to the Issuer on such vesting date. Each RSU represents the right to receive one share of common stock, par value $0.0001 per share (the "Common Stock"), of the Issuer. F2 · balance_after: Amounts adjusted for the Issuer's 1-for-25 reverse stock split of the Issuer's Common Stock, effective as of 4:05 p.m. (New York time) on April 30, 2025. Read SEC document
December 12, 2025 Filed Dec 12, 2025 22:07 UTC	PharmaCyte Biotech, Inc. PMCB · Entity 8256	Tax withholdingCommon Stock	258,750	$1.02	$263,925.00	Disclosure SEC source: 0001683168-25-009114 · ownership.xml · nonDerivative · entry 2 Silverman Joshua · CIK 0001524858 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,250 F1 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. Read SEC document
December 12, 2025 Filed Dec 12, 2025 22:07 UTC	PharmaCyte Biotech, Inc. PMCB · Entity 8256	GrantCommon Stock	575,000	$0.00	$0.00	Disclosure SEC source: 0001683168-25-009114 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 575,000 Read SEC document
November 14, 2025 Filed Nov 15, 2025 01:16 UTC	Q/C TECHNOLOGIES, INC. QCLS · Entity 7735	GrantCommon stock	91,356	$0.00	$0.00	Disclosure SEC source: 0001493152-25-023701 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,029 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs were granted to the Reporting Person on October 3, 2025, subject to stockholder approval of an amendment to the Issuer's Q/C Technologies, Inc. 2021 Equity Incentive Plan (the "Plan Amendment"), under which the RSUs were granted. The Issuer's stockholders approved the Plan Amendment on November 14, 2025. The RSUs vested immediately upon issuance. Read SEC document
October 31, 2025 Filed Oct 31, 2025 21:00 UTC	Fabric.AI, Inc. SBLX · Entity 7732	GrantEmployee Stock Option (Right to Buy · Derivative	220,513	$0.00 Strike: $6.25	$0.00	Disclosure SEC source: 0001493152-25-020432 · ownership.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,513 Underlying: Common Stock · 220,513 shares Expires 2035-10-31 F1 · derivative.exercise_date: The stock options vest as follows: (i) 75% vested upon the date of grant; and (ii) 25% will vest on December 31, 2025, provided that the Reporting Person remains employed by or providing services to the Issuer on the applicable vesting date. Read SEC document
October 17, 2025 Filed Oct 17, 2025 21:12 UTC	TAO Synergies Inc. TAOX · Entity 7482	Tax withholdingCommon Stock, par value $0.0001 per share	40,000	$7.23	$289,200.00	Disclosure SEC source: 0001104659-25-100461 · tm2529010-4_4seq1.xml · nonDerivative · entry 2 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,681 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. Read SEC document
October 17, 2025 Filed Oct 17, 2025 21:12 UTC	TAO Synergies Inc. TAOX · Entity 7482	GrantCommon Stock, par value $0.0001 per share	100,000	$0.00	$0.00	Disclosure SEC source: 0001104659-25-100461 · tm2529010-4_4seq1.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,681 F1 · balance_after: Includes (i) 100,000 restricted stock units granted on October 17, 2025, under TAO Synergies Inc.'s (the "Issuer") 2020 Equity Incentive Plan which vested immediately and (ii) 26,681 shares of common stock. Read SEC document
October 03, 2025 Filed Oct 6, 2025 21:30 UTC	Q/C TECHNOLOGIES, INC. QCLS · Entity 7735	GrantCommon stock	8,644	$0.00	$0.00	Disclosure SEC source: 0001493152-25-017132 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,673 F1 · price: Represents a grant of Restricted Stock Units ("RSUs"). The RSUs vested immediately upon grant on October 3, 2025. Read SEC document
August 06, 2025 Filed Oct 17, 2025 21:12 UTC	TAO Synergies Inc. TAOX · Entity 7482	GrantEmployee Stock Option (right to buy) · Derivative	36,000	$0.00 Strike: $10.38	$0.00	Disclosure SEC source: 0001104659-25-100461 · tm2529010-4_4seq1.xml · derivative · entry 3 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2035-07-14 F3 · date: The option grant was approved by a committee of the Issuer's board of directors on July 14, 2025 subject to shareholder approval of an amendment to the Company's 2020 Equity Incentive Plan (the "Plan") to increase the number of shares authorized for issuance of awards under the Plan. The Company received shareholder approval of the amendment to the Plan on August 6, 2025. Read SEC document
June 30, 2025 Filed Jul 2, 2025 20:06 UTC	TAO Synergies Inc. TAOX · Entity 7482	Tax withholdingCommon Stock, par value $0.0001 per share	16,768	$7.85	$131,628.80	Disclosure SEC source: 0001104659-25-065281 · tm2519649-4_4seq1.xml · nonDerivative · entry 2 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,681 F2 · shares: Represents shares withheld by the Issuer to satisfy the tax liability upon vesting of restricted stock units and does not constitute an actual sale or other open-market transaction. Read SEC document
June 30, 2025 Filed Jul 2, 2025 20:06 UTC	TAO Synergies Inc. TAOX · Entity 7482	GrantCommon Stock, par value $0.0001 per share	41,919	$0.00	$0.00	Disclosure SEC source: 0001104659-25-065281 · tm2519649-4_4seq1.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,449 F1 · balance_after: Includes (i) 41,919 restricted stock units granted on June 30, 2025, under the Issuer's 2020 Equity Incentive Plan which vested immediately upon issuance and (ii) 1,530 shares of common stock. Read SEC document
June 25, 2025 Filed Jun 27, 2025 21:25 UTC	FEMASYS INC FEMY · Entity 7510	GrantStock Option (Right to Buy) · Derivative	17,600	$0.00 Strike: $0.98	$0.00	Disclosure SEC source: 0001140361-25-024006 · form4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2035-06-25 F1 · derivative.exercise_date: The shares underlying the stock option vest one year from the date of grant, assuming continued service. Read SEC document
February 19, 2025 Filed Feb 21, 2025 22:33 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantCommon Stock	1,000,000	$0.00	$0.00	Disclosure SEC source: 0001104659-25-016201 · tm257316-3_4seq1.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,011,237 F1 · price: Represents a grant of restricted shares of common stock, par value $0.0001 per share, of the Issuer granted under the Petros Pharmaceuticals, Inc. Amended and Restated 2020 Omnibus Incentive Compensation Plan, as amended. 50% of the shares vest on the first anniversary of the date of grant and the remaining shares vest on the second anniversary on the date of grant, provided that the Reporting Person continues to provide service to the Issuer on the applicable vesting date. Read SEC document
December 02, 2024 Filed Dec 3, 2024 02:42 UTC	Fabric.AI, Inc. AYRO · Entity 7732	Exercise / conversionCash-Settled Restricted Stock Units · Derivative	97,368	$0.00	$0.00	Disclosure SEC source: 0001493152-24-048362 · ownership.xml · derivative · entry 3 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,368 Underlying: Common Stock · Not disclosed shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Represents a grant of cash-settled restricted stock units ("RSUs" and, together with the Stock Award, the "Director Equity Awards") granted by the Issuer to the Reporting Person. On the date of grant, the RSUs immediately converted into a cash payment equal to the fair market value of the number of shares of Common Stock equal to the same number of RSUs that were granted to the Reporting Person for the purpose of satisfying the Reporting Person's tax obligation with respect to the Director Equity Awards. No securities of the Issuer were issued, acquired or disposed of in connection with the grant of the RSUs. F5 · kind: Represents a grant of cash-settled restricted stock units ("RSUs" and, together with the Stock Award, the "Director Equity Awards") granted by the Issuer to the Reporting Person. On the date of grant, the RSUs immediately converted into a cash payment equal to the fair market value of the number of shares of Common Stock equal to the same number of RSUs that were granted to the Reporting Person for the purpose of satisfying the Reporting Person's tax obligation with respect to the Director Equity Awards. No securities of the Issuer were issued, acquired or disposed of in connection with the grant of the RSUs. F5 · price: Represents a grant of cash-settled restricted stock units ("RSUs" and, together with the Stock Award, the "Director Equity Awards") granted by the Issuer to the Reporting Person. On the date of grant, the RSUs immediately converted into a cash payment equal to the fair market value of the number of shares of Common Stock equal to the same number of RSUs that were granted to the Reporting Person for the purpose of satisfying the Reporting Person's tax obligation with respect to the Director Equity Awards. No securities of the Issuer were issued, acquired or disposed of in connection with the grant of the RSUs. F5 · derivative.exercise_date: Represents a grant of cash-settled restricted stock units ("RSUs" and, together with the Stock Award, the "Director Equity Awards") granted by the Issuer to the Reporting Person. On the date of grant, the RSUs immediately converted into a cash payment equal to the fair market value of the number of shares of Common Stock equal to the same number of RSUs that were granted to the Reporting Person for the purpose of satisfying the Reporting Person's tax obligation with respect to the Director Equity Awards. No securities of the Issuer were issued, acquired or disposed of in connection with the grant of the RSUs. F5 · derivative.expiration_date: Represents a grant of cash-settled restricted stock units ("RSUs" and, together with the Stock Award, the "Director Equity Awards") granted by the Issuer to the Reporting Person. On the date of grant, the RSUs immediately converted into a cash payment equal to the fair market value of the number of shares of Common Stock equal to the same number of RSUs that were granted to the Reporting Person for the purpose of satisfying the Reporting Person's tax obligation with respect to the Director Equity Awards. No securities of the Issuer were issued, acquired or disposed of in connection with the grant of the RSUs. F5 · derivative.underlying_shares: Represents a grant of cash-settled restricted stock units ("RSUs" and, together with the Stock Award, the "Director Equity Awards") granted by the Issuer to the Reporting Person. On the date of grant, the RSUs immediately converted into a cash payment equal to the fair market value of the number of shares of Common Stock equal to the same number of RSUs that were granted to the Reporting Person for the purpose of satisfying the Reporting Person's tax obligation with respect to the Director Equity Awards. No securities of the Issuer were issued, acquired or disposed of in connection with the grant of the RSUs. F4 · balance_after: The securities reported as acquired herein were granted to the Reporting Person by the Issuer in lieu of any other awards previously approved by the Issuer since the beginning of the fourth quarter of the Company's 2023 fiscal year, but were never issued by the Issuer, as an annual award grant to the Reporting Person in connection with the Reporting Person's service on the Issuer's Board of Directors for 2024 and a partial annual award grant for the Reporting Person's service on the Issuer's Board of Directors for the last quarter of 2023. Read SEC document
December 02, 2024 Filed Dec 3, 2024 02:42 UTC	Fabric.AI, Inc. AYRO · Entity 7732	GrantCommon Stock	146,052	$0.00	$0.00	Disclosure SEC source: 0001493152-24-048362 · ownership.xml · nonDerivative · entry 2 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,323 F3 · kind: Represents a grant of restricted shares of Common Stock issued under the Plan which fully vested on the date of grant (the "Stock Award"). F3 · price: Represents a grant of restricted shares of Common Stock issued under the Plan which fully vested on the date of grant (the "Stock Award"). F2 · balance_after: The securities reported herein have been adjusted for the Company's one-for-eight reverse stock split effected on September 15, 2023. F4 · balance_after: The securities reported as acquired herein were granted to the Reporting Person by the Issuer in lieu of any other awards previously approved by the Issuer since the beginning of the fourth quarter of the Company's 2023 fiscal year, but were never issued by the Issuer, as an annual award grant to the Reporting Person in connection with the Reporting Person's service on the Issuer's Board of Directors for 2024 and a partial annual award grant for the Reporting Person's service on the Issuer's Board of Directors for the last quarter of 2023. Read SEC document
December 02, 2024 Filed Dec 3, 2024 02:42 UTC	Fabric.AI, Inc. AYRO · Entity 7732	Disposition to issuerCommon Stock	6,166	$0.00	$0.00	Disclosure SEC source: 0001493152-24-048362 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · Executive Chairman 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,271 F1 · kind: Represents a forfeiture of restricted shares of common stock (the "Forfeited Shares"), par value $0.0001 per share ("Common Stock"), of the Issuer granted to the Reporting Person under the AYRO, Inc. Long-Term Incentive Plan (as amended, the "Plan") in connection with the Reporting Person's service on the Issuer's Board of Directors that vested, but were not issued to the Reporting Person, on November 1, 2023. The Reporting Person received the Director Equity Awards (as defined herein), among other reasons as described herein, in lieu of such Forfeited Shares. F1 · price: Represents a forfeiture of restricted shares of common stock (the "Forfeited Shares"), par value $0.0001 per share ("Common Stock"), of the Issuer granted to the Reporting Person under the AYRO, Inc. Long-Term Incentive Plan (as amended, the "Plan") in connection with the Reporting Person's service on the Issuer's Board of Directors that vested, but were not issued to the Reporting Person, on November 1, 2023. The Reporting Person received the Director Equity Awards (as defined herein), among other reasons as described herein, in lieu of such Forfeited Shares. F2 · balance_after: The securities reported herein have been adjusted for the Company's one-for-eight reverse stock split effected on September 15, 2023. Read SEC document
July 12, 2024 Filed Jul 15, 2024 20:39 UTC	FEMASYS INC FEMY · Entity 7510	GrantStock Option (Right to Buy) · Derivative	17,600	$0.00 Strike: $1.14	$0.00	Disclosure SEC source: 0001140361-24-033183 · form4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,600 Underlying: Common Stock · 17,600 shares Expires 2034-07-12 F1 · derivative.exercise_date: The shares underlying the stock option vest one year from the date of grant, assuming continued service. Read SEC document
April 08, 2024 Filed Apr 10, 2024 20:07 UTC	TAO Synergies Inc. SNPX · Entity 7482	GrantStock Option (Right to Buy) · Derivative	800	$0.00 Strike: $5.39	$0.00	Disclosure SEC source: 0001104659-24-045802 · tm2411531-3_4seq1.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800 Underlying: Common Stock, par value $0.0001 per share · 800 shares Expires 2034-04-08 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following April 8, 2024. Read SEC document
December 21, 2023 Filed Dec 26, 2023 22:06 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $1.41	$0.00	Disclosure SEC source: 0001104659-23-129250 · tm2333705-1_4seq1.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-12-21 F1 · derivative.exercise_date: The stock options will vest on April 10, 2024, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. through the vesting date. Read SEC document
November 21, 2023 Filed Nov 22, 2023 21:39 UTC	FEMASYS INC FEMY · Entity 7510	GrantStock Option (Right to Buy) · Derivative	17,000	$0.00 Strike: $0.90	$0.00	Disclosure SEC source: 0001140361-23-054461 · form4.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-11-21 F1 · derivative.exercise_date: The shares underlying the stock option will vest in annual one-third (1/3) increments over a three (3) year period beginning on November 21, 2024, assuming continued service. Read SEC document
November 20, 2023 Filed Nov 22, 2023 22:01 UTC	PharmaCyte Biotech, Inc. PMCB · Entity 8256	GrantStock Option (Right to Buy) · Derivative	170,000	$0.00 Strike: $2.18	$0.00	Disclosure SEC source: 0001683168-23-008431 · ownership.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director · Interim CEO, Interim President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2033-11-20 F1 · derivative.exercise_date: The options vest 50% on November 20, 2023 and 50% on November 20, 2024. Read SEC document
August 01, 2023 Filed Aug 4, 2023 00:02 UTC	Fabric.AI, Inc. AYRO · Entity 7732	SaleCommon Stock	12,740	$0.82	$10,385.65	Disclosure SEC source: 0001493152-23-026686 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 395,493 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8002 to $0.8450, inclusive. The reporting person undertakes to provide to AYRO, Inc., any security holder of AYRO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Represents a broker-assisted sale of shares subject to a 10b5(1) trading plan adopted by the reporting person on February 16, 2023 to pay taxes upon the vesting of an award. Read SEC document
June 07, 2023 Filed Jun 9, 2023 22:00 UTC	Q/C TECHNOLOGIES, INC. MYMD · Entity 7735	GrantEmployee Stock Option (Right to Buy) · Derivative	200,000	$0.00 Strike: $1.66	$0.00	Disclosure SEC source: 0001493152-23-020798 · ownership.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-06-07 F1 · derivative.exercise_date: The stock options vest as follows: (i) one third on the date of grant; (ii) one third on the first anniversary of the date of grant; and (iii) one third on the second anniversary of the date of grant, provided that the Reporting Person remains employed by MyMD Pharmaceuticals, Inc. or a subsidiary on the applicable vesting date. Read SEC document
May 03, 2023 Filed May 5, 2023 23:51 UTC	Fabric.AI, Inc. AYRO · Entity 7732	SaleCommon Stock	11,927	$0.49	$5,813.22	Disclosure SEC source: 0001493152-23-015692 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 408,233 F1 · price: Represents a broker-assisted sale of shares subject to a 10b5(1) trading plan adopted by the reporting person on February 16, 2023 to pay taxes upon the vesting of an award. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4700 to $0.5001, inclusive. The reporting person undertakes to provide to AYRO, Inc., any security holder of AYRO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document
April 26, 2023 Filed Apr 28, 2023 22:00 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	Exercise / conversionRestricted Stock Units · Derivative	6,722	$0.00	$0.00	Disclosure SEC source: 0001104659-23-053224 · tm2313909-1_4seq1.xml · derivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,722 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer. F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. F2 · derivative.exercise_date: On April 7, 2022, the reporting person was granted 6,722 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023. F2 · derivative.expiration_date: On April 7, 2022, the reporting person was granted 6,722 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023. F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. Read SEC document
April 26, 2023 Filed Apr 28, 2023 22:00 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	Exercise / conversionCommon Stock	6,722	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-053224 · tm2313909-1_4seq1.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,237 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. F2 · price: On April 7, 2022, the reporting person was granted 6,722 restricted stock units, vesting on April 7, 2023, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on April 26, 2023. F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. Read SEC document
April 10, 2023 Filed Apr 12, 2023 22:01 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	GrantStock Option (Right to Buy) · Derivative	39,000	$0.00 Strike: $0.99	$0.00	Disclosure SEC source: 0001104659-23-044712 · tm2312600-3_4seq.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires 2033-04-10 F1 · derivative.exercise_date: The stock options will vest on the one-year anniversary of the date of grant, provided that the Reporting Person has continued to provide services to Petros Pharmaceuticals, Inc. (the "Company") through the vesting date. Read SEC document
March 29, 2023 Filed Mar 31, 2023 20:15 UTC	TAO Synergies Inc. SNPX · Entity 7482	GrantStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $0.87	$0.00	Disclosure SEC source: 0001104659-23-040186 · tm2311075-1_4seq1.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 per share · 20,000 shares Expires 2033-03-29 F1 · derivative.exercise_date: All of the holder's options shall vest and become immediately exercisable upon the holder's completion of one year of service following March 29, 2023. Read SEC document
February 01, 2023 Filed Feb 3, 2023 23:29 UTC	Fabric.AI, Inc. AYRO · Entity 7732	GrantCommon Stock	197,333	$0.00	$0.00	Disclosure SEC source: 0001493152-23-003577 · ownership.xml · nonDerivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,160 F2 · shares: Shares will vest in four equal installments on each quarterly anniversary of the Grant Date, provided that Mr. Silverman is employed by or providing services to the Company through the applicable vesting date and subject to the terms and conditions of the AYRO, Inc. Long-Term Incentive Plan. Read SEC document
January 30, 2023 Filed Feb 3, 2023 23:29 UTC	Fabric.AI, Inc. AYRO · Entity 7732	SaleCommon Stock	7,171	$0.71	$5,107.90	Disclosure SEC source: 0001493152-23-003577 · ownership.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 222,827 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7000 to $0.7375, inclusive. The reporting person undertakes to provide to AYRO, Inc., any security holder of AYRO, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Represents a broker-assisted sale of shares subject to a 10b5(1) trading plan adopted by the reporting person on August 22, 2022 to pay taxes upon the vesting of an award. Read SEC document
January 20, 2023 Filed Jan 25, 2023 21:17 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	Exercise / conversionRestricted Stock Units · Derivative	2,515	$0.00	$0.00	Disclosure SEC source: 0001104659-23-006546 · tm234334-3_4seq1.xml · derivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,515 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one share of common stock of the Issuer. F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. F2 · derivative.exercise_date: On December 22, 2021, the reporting person was granted 2,515 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023. F2 · derivative.expiration_date: On December 22, 2021, the reporting person was granted 2,515 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023. F1 · derivative.underlying_shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. Read SEC document
January 20, 2023 Filed Jan 25, 2023 21:17 UTC	Petros Pharmaceuticals, Inc. PTPI · Entity 8730	Exercise / conversionCommon Stock	2,515	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-006546 · tm234334-3_4seq1.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. F2 · price: On December 22, 2021, the reporting person was granted 2,515 restricted stock units, vesting on December 22, 2022, subject to the reporting person's employment on that date. Such restricted stock units were converted into common stock on a one-for-one basis (after adjusting for the Reverse Stock Split) on January 20, 2023. F1 · balance_after: On November 30, 2022, Petros Pharmaceuticals, Inc. effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"), effective as of 4:05 p.m., New York time. All share amounts reported herein have been adjusted to give effect to the Reverse Stock Split. Read SEC document
December 16, 2022 Filed Dec 21, 2022 01:01 UTC	TAO Synergies Inc. SNPX · Entity 7482	SaleCommon Stock, par value $0.0001 per share	19,012	$1.17	$22,280.16	Disclosure SEC source: 0001104659-22-128770 · tm2233089-5_4seq1.xml · nonDerivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,238 F1 · shares: Shares sold pursuant to a Rule 10b5-1 sales plan, entered into on December 6, 2021 and amended and restated on October 24, 2022, to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. Read SEC document
November 15, 2022 Filed Nov 17, 2022 21:03 UTC	TAO Synergies Inc. SNPX · Entity 7482	GrantStock Option (Right to Buy) · Derivative	144,000	$0.00 Strike: $6.07	$0.00	Disclosure SEC source: 0001104659-22-119881 · tm2230820-6_4seq1.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 Underlying: Common Stock, par value $0.0001 per share · 144,000 shares Expires 2032-11-15 F1 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer. Read SEC document
November 15, 2022 Filed Dec 2, 2022 00:50 UTC Amendment	TAO Synergies Inc. SNPX · Entity 7482	GrantStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $6.07	$0.00	Disclosure SEC source: 0001104659-22-123802 · tm2231816-4_4aseq1.xml · derivative · entry 1 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock, par value $0.0001 per share · 75,000 shares Expires 2032-11-15 F1 · shares: This filing amends the Form 4, filed on November 17, 2022 by Mr. Silverman to reflect the lower number of options allowed to be granted pursuant to the per-participant grant limit contained in the Issuer's 2020 Equity Incentive Plan, as amended. F2 · derivative.exercise_date: These options vested 50% on November 15, 2022 (the "Issuance Date") and shall vest 50% on the six-month anniversary of the Issuance Date. The options shall be exercisable for a period of ten years from the date of the grant, irrespective of whether or not the reporting person continues to provide services to the Issuer. Read SEC document
November 01, 2022 Filed Nov 4, 2022 01:04 UTC	Fabric.AI, Inc. AYRO · Entity 7732	SaleCommon Stock	7,171	$0.59	$4,244.51	Disclosure SEC source: 0001493152-22-030401 · ownership.xml · nonDerivative · entry 2 Silverman Joshua · CIK 0001524858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,998 F2 · shares: Represents a broker-assisted sale of shares to pay taxes upon the vesting of an award. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.